ID: ALA4878870

Max Phase: Preclinical

Molecular Formula: C25H30N4O5S

Molecular Weight: 498.61

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  COc1ncc(C2=CCOCC2)cc1S(=O)(=O)Nc1cncc(C#CCN2C[C@@H](C)O[C@@H](C)C2)c1

Standard InChI:  InChI=1S/C25H30N4O5S/c1-18-16-29(17-19(2)34-18)8-4-5-20-11-23(15-26-13-20)28-35(30,31)24-12-22(14-27-25(24)32-3)21-6-9-33-10-7-21/h6,11-15,18-19,28H,7-10,16-17H2,1-3H3/t18-,19+

Standard InChI Key:  BHKDTJDECRFNNM-KDURUIRLSA-N

Associated Targets(Human)

PI3-kinase p110-delta/p85-alpha 1508 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3-kinase p110-alpha/p85-alpha 2589 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3K p110 beta/p85 alpha 919 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3-kinase p110-gamma subunit 5411 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3-kinase p110-delta subunit 6699 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 498.61Molecular Weight (Monoisotopic): 498.1937AlogP: 2.55#Rotatable Bonds: 6
Polar Surface Area: 102.88Molecular Species: NEUTRALHBA: 8HBD: 1
#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 7.09CX Basic pKa: 5.99CX LogP: 1.53CX LogD: 1.37
Aromatic Rings: 2Heavy Atoms: 35QED Weighted: 0.61Np Likeness Score: -1.06

References

1. Down K, Amour A, Anderson NA, Barton N, Campos S, Cannons EP, Clissold C, Convery MA, Coward JJ, Doyle K, Duempelfeld B, Edwards CD, Goldsmith MD, Krause J, Mallett DN, McGonagle GA, Patel VK, Rowedder J, Rowland P, Sharpe A, Sriskantharajah S, Thomas DA, Thomson DW, Uddin S, Hamblin JN, Hessel EM..  (2021)  Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.,  64  (18.0): [PMID:34510892] [10.1021/acs.jmedchem.1c01102]

Source